RET and hepatocellular carcinoma: Lenvatinib, an inhibitor of epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), VEGFR, PDGFR, RET, and C-kit, emerged almost a decade after sorafenib as an alternative first-line treatment for advanced HCC.